Information Provided By:
Fly News Breaks for May 19, 2017
ALKS
May 19, 2017 | 07:19 EDT
Credit Suisse analyst Vamil Divan said he views the additional ALKS 5461 FORWARD-5 study data that Alkermes presented as an incremental positive, adding that the safety profile of the prospective depression treatment also seems clean. A "leading psychiatrist" that Divan met with now feels more comfortable that the data for ALKS 5461 should be sufficient for FDA approval, the analyst tells investors. He keeps an Outperform rating and $70 target price on Alkermes shares.
News For ALKS From the Last 2 Days
ALKS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.